Clinical Trial

Adaptive RadioTherapy for OroPharynx Cancer

Study acronym: ART-OPC
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 12, 2023 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to systematic mid-treatment MRI-based radiotherapy adaptation vs. standard of care. The primary objective is to compare patient-rated dysphagia (as assessed by the MD Anderson Dysphagia Inventory composite score at 6 months post-treatment in patients undergoing routine mid-treatment MR-guided radiotherapy adaptation vs. in patients receiving the current standard of care.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-05-24; most recent amendment 2023-12-11.
Status change: Not Yet Recruiting → Recruiting 2021-07-30
Trial Details
NCT Number NCT04901234
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators: Austin Health
Conditions Oropharynx Cancer, Radiotherapy; Complications, Radiotherapy Side Effect, Dysphagia, MRI
Enrollment 120 participants
Start Date 2021-07-30
Primary Completion 2024-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2023-12-12